Welcome to our dedicated page for Scilex Holding Company news (Ticker: SCLXW), a resource for investors and traders seeking the latest updates and insights on Scilex Holding Company stock.
Scilex Holding Company (Nasdaq: SCLX) is a healthcare company focused on non-opioid pain management products and related therapeutic areas, with its publicly listed warrants trading under the symbol SCLXW. The Scilex news stream highlights how the company advances its commercial portfolio, develops late-stage product candidates, and structures financing and strategic transactions that can affect both SCLX common stock and SCLXW warrants.
News coverage commonly features updates on Scilex’s commercial products ZTlido ae, ELYXYB ae, and Gloperba ae, as well as its product candidates SP-102 (SEMDEXA ae or SP-102), SP-103, and SP-104. Press releases also describe regulatory designations such as FDA Fast Track status for SP-102 and SP-103, progress in clinical development, and collaborations through its majority-owned subsidiary Semnur Pharmaceuticals, Inc.
Investors following SCLXW can also expect frequent announcements on capital markets activity and corporate finance, including warrant exercises and exchanges, equity lines of credit, and warrant repurchase options. Recent filings describe transactions with Oramed Pharmaceuticals Inc., a Common Stock Purchase Agreement with an institutional investor, and other arrangements that may influence the company’s capital structure and the economic profile of its warrants.
Another recurring theme in Scilex news is its relationship with Datavault AI Inc. (Nasdaq: DVLT). Releases detail Scilex’s strategic investment in Datavault AI, a worldwide exclusive license to Datavault AI’s AI-driven tokenization technology for biotech and biopharma applications, and co-sponsored initiatives such as the Dream Bowl 2026 Meme Coin distributions to Scilex shareholders. Updates on these initiatives provide context on how Scilex is exploring data tokenization, biotech exchanges, and shareholder-focused digital assets.
For readers tracking SCLXW, the news feed offers insight into Scilex’s operating focus, pipeline milestones, financing decisions, and technology partnerships. Regular review of these items can help contextualize movements in both the common stock and the associated warrants.
Scilex Holding Company (Nasdaq: SCLX), a company focused on non-opioid pain management products, has announced the deferral of its previously announced dividend record date. The dividend, which consists of Scilex preferred stock exchangeable for up to 10% of Scilex's ownership interest in Semnur Pharmaceuticals, was originally scheduled for May 2, 2025.
The Board of Directors will determine a new record date at their discretion and maintains the right to further modify the date or revoke the dividend entirely. This dividend would affect both stockholders and certain other securityholders of Scilex.
Scilex Holding Company (NASDAQ: SCLX) presented a post-hoc analysis of their C.L.E.A.R. trial at the 27th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP). The analysis focused on interpreting the clinical meaningfulness of SP-102 (SEMDEXA™) for treating lumbosacral radicular pain (LRP).
The results demonstrated that SP-102 showed clinically meaningful separation from placebo across multiple endpoints, including NPRS Responder Analyses, ODI, and BPI Pain Interference. The effectiveness was particularly notable in the modified intent-to-treat (mITT) population. When compared to other marketed analgesics for chronic low back pain and TSIs, SP-102's standard effect size showed promising results.
The drug was specifically formulated to provide a safer alternative to current off-label products that carry warnings of potentially dangerous and life-threatening adverse events. The overall benefit-risk profile suggests SP-102 could be a safe and effective treatment option for LRP patients.
Scilex Holding Company (NASDAQ: SCLX) announced it will present a post-hoc analysis of their C.L.E.A.R. trial (Corticosteroid Lumbar Epidural Analgesia in Radiculopathy) at the 27th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP) from May 15-17, 2025 in Orlando, FL. The presentation will focus on interpreting the clinical meaningfulness of safety and efficacy data for SP-102 (SEMDEXA™) in treating lumbosacral radicular pain (LRP).
The poster presentation will be displayed throughout the meeting and will be accessible via the conference app. Additionally, it will be published in the Pain Physician journal. The research was conducted by a team of authors including Miller AM, Knezevic NN, Nalamachu S, and others.
Scilex Holding Company has successfully regained compliance with Nasdaq's minimum bid price requirement. The company, trading under the symbol SCLX, met the crucial requirement of maintaining a minimum closing bid price of $1.00 per share for at least ten consecutive trading days, achieving this milestone on April 30, 2025.
As a result, Scilex will continue trading on the Nasdaq Capital Market under the symbols "SCLX" for common stock and "SCLXW" for public warrants. The company specializes in non-opioid pain management products, focusing on treatments for acute and chronic pain, along with neurodegenerative and cardiometabolic diseases.
This compliance achievement ensures Scilex maintains its position on the Nasdaq exchange, providing stability for this revenue-generating pharmaceutical company that develops and commercializes innovative pain management solutions.